Index
S&P 500
Market Cap
111.95B
Enterprise Value
124.11B
Income
3.62B
Sales
26.30B
Book/sh
61.62
Cash/sh
8.53
Employees
56000
IPO
Mar 17, 1980
P/E
31.09
Forward P/E
17.83
PEG
1.77
P/S
4.26
P/B
4.74
P/C
34.22
P/FCF
24.48
EV/EBITDA
16.19
EV/Sales
4.72
Quick Ratio
1.30
Current Ratio
2.18
Debt/Eq
0.66
LT Debt/Eq
0.62
Option/Short
Yes / Yes
EPS (ttm)
9.39
EPS next Y
16.36
EPS next Q
5.03
EPS this Y
9.02%
EPS next Y
10.13%
EPS next 5Y
10.08%
EPS past 3/5Y
10.83% 14.84%
Sales past 3/5Y
10.83% 11.84%
EPS Y/Y TTM
22.82%
Sales Y/Y TTM
7.87%
EPS Q/Q
-11.88%
Sales Q/Q
7.64%
Insider Own
5.88%
Insider Trans
-2.90%
Inst Own
83.66%
Inst Trans
0.93%
ROA
7.68%
ROE
16.02%
ROIC
9.54%
Gross Margin
63.21%
Oper. Margin
24.56%
Profit Margin
13.78%
SMA20
-0.34%
SMA50
-0.29%
SMA200
-9.87%
Trades
Shs Outstand
380.70M
Shs Float
361.01M
52W High
389.33 -25.04%
52W Low
267.00 9.31%
Volatility
3.04% 2.81%
ATR (14)
9.70
RSI (14)
47.98
Beta
0.80
Rel Volume
2.42
Avg Volume
2.66M
Volume
6,438,161
Perf Week
-4.98%
Perf Month
6.92%
Perf Quarter
-14.46%
Perf Half Y
-0.97%
Perf YTD
-16.96%
Perf Year
-20.90%
Perf 3Y
11.15%
Perf 5Y
9.69%
Perf 10Y
155.41%
Prev Close
311.75
Price
291.86
Change %
-6.38%
Analysts 17 incl. previous ratings
Rating Distribution 12 Buy · 5 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Oct 30, 2026 Downgrade C Canaccord Genuity
Buy → Hold $300 +2.8% Oct 07, 2026 Initiated B Barclays
Overweight $375 +28.5% Aug 13, 2026 Downgrade W Wolfe Research
Outperform → Peer Perform Jul 28, 2026 Resumed U UBS
Buy $400 +37.1% Jul 09, 2026 Initiated B BMO Capital Markets
Outperform $369 +26.4% Apr 13, 2026 Initiated L Leerink Partners
Outperform $410 +40.5% Feb 20, 2026 Initiated W William Blair
Outperform Jan 27, 2026 Resumed T TD Cowen
Hold $387 +32.6% Jan 06, 2026 Upgrade R Raymond James
Mkt Perform → Outperform $418 +43.2% Dec 19, 2025 Upgrade C Citizens JMP
Mkt Perform → Mkt Outperform $440 +50.8% Sep 18, 2025 Initiated R Rothschild & Co Redburn
Neutral $420 +43.9% Feb 26, 2025 Resumed C Citigroup
Buy $450 +54.2% Dec 02, 2024 Upgrade M Morgan Stanley
Equal-Weight → Overweight $370 → $445 +52.5% Sep 10, 2024 Initiated W Wolfe Research
Outperform $405 +38.8% May 30, 2024 Initiated G Goldman
Neutral $372 +27.5% May 22, 2024 Upgrade N Needham
Hold → Buy $392 +34.3% Jan 31, 2024 Upgrade C Canaccord Genuity
Hold → Buy $315 → $360 +23.3% Oct 20, 2023 Initiated R ROTH MKM
Buy $345 +18.2% Sep 05, 2023 Upgrade B BofA Securities
Neutral → Buy $310 → $315 +7.9% Mar 29, 2023 Initiated U UBS
Neutral $287 -1.7%
Show Previous Ratings
Oct-30-26 01:39PM
10:23AM
Oct-29-26 07:15PM
04:24PM
04:05PM
04:00PM
Loading…
Oct-27-26 04:00PM
08:00AM
Oct-26-26 10:24AM
08:00AM
Oct-22-26 07:40AM
06:56AM
Oct-21-26 05:30AM
(The Wall Street Journal)
Oct-15-26 05:01PM
03:18PM
Oct-14-26 04:55PM
09:03AM
Loading…
09:03AM
Oct-12-26 01:16PM
12:48PM
12:16PM
08:30AM
08:00AM
Oct-07-26 10:00AM
Oct-06-26 04:32PM
(Investor's Business Daily)
02:01PM
11:36AM
10:02AM
08:18AM
08:00AM
Oct-02-26 04:47AM
Oct-01-26 02:21PM
08:00AM
Loading…
08:00AM
Sep-29-26 03:26PM
Sep-28-26 03:09PM
12:49PM
Sep-24-26 02:45PM
Sep-22-26 09:29AM
Sep-21-26 11:05AM
Sep-18-26 08:33AM
Sep-17-26 03:06PM
12:31PM
12:20PM
Sep-16-26 09:06AM
Sep-15-26 03:00PM
Sep-14-26 02:16PM
10:34AM
Sep-11-26 02:50PM
Sep-10-26 08:06AM
Sep-09-26 04:22PM
02:06PM
Sep-08-26 04:30PM
11:31AM
Sep-04-26 06:32PM
02:25PM
Sep-02-26 03:37PM
01:52PM
06:00AM
Sep-01-26 01:02PM
09:05AM
Aug-31-26 08:47PM
04:05PM
Aug-27-26 08:12PM
03:00PM
12:29PM
Aug-26-26 03:51PM
06:48AM
Aug-25-26 12:05PM
11:08AM
Aug-21-26 02:01PM
Aug-13-26 05:21PM
08:37AM
Aug-12-26 05:37PM
01:20PM
06:58AM
Aug-10-26 02:14PM
Aug-05-26 09:34AM
Jul-31-26 04:30PM
07:53AM
07:23AM
01:04AM
Jul-30-26 04:41PM
(The Wall Street Journal)
04:20PM
04:05PM
Jul-29-26 09:46AM
Jul-28-26 09:34AM
Jul-24-26 08:47AM
Jul-21-26 02:55PM
02:43PM
08:22AM
Jul-20-26 03:15PM
02:21PM
Jul-16-26 09:59AM
09:05AM
Jul-15-26 02:33PM
01:20PM
Jul-14-26 04:30PM
02:06PM
08:52AM
Jul-09-26 09:40AM
09:29AM
Jul-08-26 12:41PM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Crotty Dylan Bram Group President Aug 21 '26 Sale 328.61 441 144,915 6,102 Aug 26 04:33 PM STRYKER RONDA E Director Aug 18 '26 Sale 335.90 300,000 100,770,963 2,301,375 Aug 20 05:12 PM STRYKER RONDA E Director Aug 19 '26 Sale 340.10 50,000 17,005,165 2,251,375 Aug 20 05:12 PM King Debra See Remarks Aug 18 '26 Sale 336.30 826 277,787 6,210 Aug 18 04:34 PM Debra King Officer Aug 18 '26 Proposed Sale 336.30 826 277,786 Aug 18 12:44 PM STRYKER RONDA E Director Aug 18 '26 Proposed Sale 335.00 350,000 117,250,000 Aug 17 10:13 AM Fletcher Robert S VP, Chief Legal Officer May 28 '26 Sale 306.87 4,544 1,394,409 10,582 May 29 04:59 PM STRYKER RONDA E Director May 26 '26 Sale 312.23 310,000 96,792,669 1,924,880 May 28 05:22 PM Fletcher Robert S Officer May 28 '26 Proposed Sale 305.59 4,544 1,388,601 May 28 04:48 PM STRYKER RONDA E Director May 26 '26 Proposed Sale 313.00 310,000 97,030,000 May 27 08:49 AM Fink M Kathryn VP, Chief HR Officer May 08 '26 Option Exercise 167.98 21,582 3,625,388 34,719 May 12 04:37 PM Fink M Kathryn VP, Chief HR Officer May 11 '26 Sale 283.85 5,220 1,481,671 13,137 May 12 04:37 PM Fink M Kathryn VP, Chief HR Officer May 11 '26 Sale 283.45 3,500 992,085 177 May 12 04:37 PM Mary Fink Officer May 11 '26 Proposed Sale 283.84 5,220 1,481,665 May 11 03:27 PM 2023 Mary Fink Living Trust Officer May 11 '26 Proposed Sale 283.40 3,500 991,884 May 11 03:11 PM Stiles Spencer S President and COO Mar 21 '26 Option Exercise 0.00 430 0 84,324 Mar 24 05:17 PM Pierce James Andrew Group President Mar 21 '26 Option Exercise 0.00 430 0 88,676 Mar 24 05:14 PM Menon Viju Group President Mar 21 '26 Option Exercise 0.00 269 0 22,100 Mar 24 05:11 PM Lobo Kevin Chair and CEO Mar 21 '26 Option Exercise 0.00 1,452 0 248,723 Mar 24 05:07 PM Fletcher Robert S VP, Chief Legal Officer Mar 21 '26 Option Exercise 0.00 225 0 18,510 Mar 24 05:04 PM Fink M Kathryn VP, Chief HR Officer Mar 21 '26 Option Exercise 0.00 150 0 18,701 Mar 24 04:59 PM STRYKER RONDA E Director Feb 05 '26 Sale 363.95 250,000 90,988,528 2,207,331 Feb 06 06:21 PM STRYKER RONDA E Director Feb 04 '26 Sale 362.92 250,000 90,730,741 2,457,331 Feb 06 06:21 PM Lobo Kevin Chair and CEO Feb 06 '26 Option Exercise 96.64 206,955 20,000,131 329,350 Feb 06 04:18 PM Stiles Spencer S President and COO Feb 03 '26 Option Exercise 96.64 13,840 1,337,498 76,674 Feb 04 05:00 PM Pierce James Andrew Group President Feb 02 '26 Option Exercise 96.64 13,840 1,337,498 79,470 Feb 03 04:09 PM Pierce James Andrew Group President Feb 02 '26 Sale 368.87 475 175,215 70,563 Feb 03 04:09 PM James Andrew Pierce Officer Feb 02 '26 Proposed Sale 368.87 475 175,214 Feb 02 03:09 PM Silvernail Andrew K Director Jan 15 '26 Option Exercise 96.64 4,570 441,645 18,932 Jan 16 04:42 PM STRYKER RONDA E Director Jan 14 '26 Option Exercise 96.64 4,570 441,645 5,783 Jan 14 05:35 PM Wells Preston Wendell VP, Chief Financial Officer Nov 20 '25 Sale 365.88 165 60,370 6,694 Nov 20 04:22 PM Preston Wells Officer Nov 20 '25 Proposed Sale 365.88 165 60,370 Nov 20 12:03 PM Berry William E Jr VP, Chief Accounting Officer Nov 14 '25 Option Exercise 154.14 4,925 759,139 7,758 Nov 17 04:21 PM Berry William E Jr VP, Chief Accounting Officer Nov 14 '25 Sale 365.49 1,953 713,802 2,833 Nov 17 04:21 PM William Berry Jr Officer Nov 14 '25 Proposed Sale 365.49 2,026 740,482 Nov 14 04:27 PM STRYKER RONDA E Director Nov 06 '25 Sale 353.28 276,173 97,565,694 2,702,108 Nov 07 04:22 PM STRYKER RONDA E Director Nov 05 '25 Sale 356.98 243,827 87,040,447 2,978,281 Nov 07 04:22 PM STRYKER RONDA E Director Nov 05 '25 Proposed Sale 355.00 520,000 184,600,000 Nov 05 03:40 PM
Stryker Corp. is a medical technology company, which engages in the provision of products and services that help improve patient and healthcare outcomes. It operates under the MedSurg and Neurotechnology, and Orthopaedics and Spine segments. The MedSurg and Neurotechnology segment includes surgical equipment and navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication, workflow solutions, products for the treatment of acute ischemic and hemorrhagic stroke, traditional brain, and open skull based surgical procedures, orthobiologic, and biosurgery. The Orthopaedics and Spine segment focuses on implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar, and interbody systems used in spinal injury, deformity, and degenerative therapies. The company was founded by Homer H. Stryker in 1941 and is headquartered in Portage, MI.
Chairman & CEO Mr. Kevin A. Lobo
President & COO Mr. Spencer S. Stiles
VP & CFO Mr. Preston W. Wells
Group President of Global Quality & Operations Mr. Viju S. Menon
Group President of MedSurg & Neurotechnology Mr. J. Andrew Pierce